Growing demand for weight-loss solutions has catapulted pharmaceutical firms like Eli Lilly (LLY) and Novo Nordisk (NVO) into the spotlight, with their drugs Ozempic, Mounjaro, Zepbound and Wegovy, becoming household names.
A lesser-known player, Allurion Technologies (ALUR), is carving a niche with its innovative solutions. The Massachusetts-based medical technology firm plans to test its gastric balloon-based Allurion Program alongside GLP-1 agonists, aiming to enhance muscle retention during weight loss.
